MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay

Stock Information for Myriad Genetics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Myriad Genetics Inc.

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced - Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.